Quantum rods as nanocarriers of gene therapy

Drug Delivery

Volumn 19, Issue 4, 2012, Pages 220-231

  Aalinkeel, Ravikumar ^a   Nair, Bindukumar ^a   Reynolds, Jessica L ^a   Sykes, Donald E ^a   Law, Wing Cheung ^b   Mahajan, Supriya D ^b   Prasad, Paras N ^b   Schwartz, Stanley A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antisense oligonucleotides; Gene delivery; Nanoparticles; Quantum rods; SiRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA CYCLODEXTRIN; CADMIUM; DOXORUBICIN; GELATINASE B; INTERLEUKIN 8; NANOCARRIER; NANOROD; PHOSPHOPROTEIN DARPP 32; PROTEIN P30; QUANTUM DOT; QUANTUM ROD; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER THERAPY; CYTOTOXICITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; NANOMEDICINE; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; NANOTUBES; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84861836172     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.690001     Document Type: Article

References (128)

1. Dean NM. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr Opin Biotechnol. 2001; 12:622-625.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiol biomarker prev. 2010;19:1893-1907.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
4. Morris MJ, Tong W P, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Raf M, DiPaola RS, Rosen N, Scher HI. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 2002; 8:679-683.
5. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2002; 8:2530-2535.
6. Morris MJ, Tong W P, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Raf M, DiPaola RS, Rosen N, Scher HI. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 2002; 8:679-683.
7. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs. 2006; 24:159-167.
8. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specifc oligodeoxyribonucleotide. Proc Natl Acad Sci USA. 1978; 75:285-288.
9. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specifc oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978; 75:280-284.
10. Pan WH, Clawson GA. Antisense applications for biological control. J Cell Biochem. 2006; 98:14-35.
11. Gallo M, Montserrat JM, Iribarren AM. Design and applications of modifed oligonucleotides. Braz J Med Biol Res. 2003; 36:143-151.
12. Gao WY, Han FS, Storm C, Egan W, Cheng YC. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 41:223-229.
13. Gibson I. Antisense approaches to the gene therapy of cancer-'Recnac'. Cancer Metastasis Rev. 1996; 15:287-299.
14. Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 1992; 10:152-158.
15. Agrawal S, Kandimalla ER. ntisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets. 2001; 1:197-209.
16. Agris PF, Smith S, Fu C, Simkins SG. QC in antisense oligo synthesis. Nat Biotechnol. 2002; 20:871-872.
17. Bennett CF. Efciency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev. 2002; 12:215-224.
18. Bennett CF, Cowsert LM. Application of antisense oligonucleotides for gene functionalization and target validation. Curr Opin Mol Ter. 1999; 1:359-371.
19. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59:75-86.
20. Wang W, Chen C, Lin KH, Fang Y, Lieber CM. Nanosensors. Google Patents; 2005.
21. Kumar CSS. Nanomaterials for Medical Applications. Kirk-Othmer Encyclopedia of Chemical Technology. 2007.
22. Kluson P, Drobek M, Bartkova H, Budil I. Welcome in the Nanoworld. Chem Listy. 2007;101:262-272.
23. Kral V, Šotola J, Neuwirth P, Kejik Z, Zaruba K, Martasek P. Nanomedicine-Current Status and Perspectives: A Big Potential or Just a Catchword? Feedback. 1997;91.
24. Eftekhari A. Nanostructured materials in electrochemistry: Vch Verlagsgesellschaft Mbh; 2008.
25. Ghanem MA, Bartlett PN, De Groot P, Zhukov A. A double templated electrodeposition method for the fabrication of arrays of metal nanodots. Electrochem comm. 2004;6:447-453.
26. Fujioka K, Hiruoka M, Sato K, Manabe N, Miyasaka R, Hanada S, Hoshino A, Tilley RD, Manome Y, Hirakuri K, Yamamoto K. Luminescent passive-oxidized silicon quantum dots as biological staining labels and their cytotoxicity effects at high concentration. Nanotechnology. 2008; 19:415102.
27. Bandyopadhyay S, Nalwa HS. Quantum dots and nanowires. StevensonRanch, California: American Scientifc Publishers; 2003.
28. Htoon H, Hollingworth J, Malko A, Dickerson R, Klimov V. Light amplifcation in semiconductor nanocrystals: Quantum rods versus quantum dots. Applied physics letters. 2003;82:4776.
29. Shabaev A, Efros AL. 1D exciton spectroscopy of semiconductor nanorods. Nano letters. 2004;4:1821-1825.
30. Hu J, Li Ls, Yang, W, Manna L, Wang Lw, Alivisatos AP. Linearly polarized emission from colloidal semiconductor quantum rods. Science. 2001; 292:2060-2063.
31. Rothenberg E, Kazes M, Shaviv E, Banin U. Electric field induced switching of the fuorescence of single semiconductor quantum rods. Nano Lett. 2005; 5:1581-1586.
32. Fattal E, Barratt G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol. 2009; 157:179-194.
33. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464:1067-1070.
34. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009; 8:526-533.
35. Zhao MX, Li JM, Du L, Tan CP, Xia Q, Mao ZW, Ji LN. Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with ß-cyclodextrin coupled to amino acids. Chemistry. 2011; 17:5171-5179.
36. Li JM, Zhao MX, Su H, Wang YY, Tan CP, Ji LN, Mao ZW. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. Biomaterials. 2011; 32:7978-7987.
37. Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV, Chen J, Eisen HN, Langer R. Poly-β amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA. 2004; 101:9534-9539.
38. Zou J, Hew CC, Temistou E, Li Y, Chen CK, Alexandridis P, Cheng C. Clicking well-defned biodegradable nanoparticles and nanocapsules by UV-induced thiol-ene cross-linking in transparent miniemulsions. Adv Mater Weinheim. 2011; 23:4274-4277.
39. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm. 2008; 364:237-248.
40. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm. 2009; 71:490-504.
41. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs. 2010; 24:195-205.
42. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008; 36:4158-4171.
43. Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother. 2006; 60:607-620.
44. Deka S, Quarta A, Lupo MG, Falqui A, Boninelli S, Giannini C, et al. CdSe/CdS/ZnS double shell nanorods with high photoluminescence efciency and their exploitation as biolabeling probes. J Am Chem Soc. 2009;131:2948-2958. Epub 2009/02/12.
45. Sitt A, Salant A, Menagen G, Banin U. Highly emissive nano rodin-rod heterostructures with strong linear polarization. Nano Lett. 2011; 11:2054-2060.
46. Aaron JS, Greene AC, Kotula PG, Bachand GD, Timlin JA. Advanced optical imaging reveals the dependence of particle geometry on interactions between CdSe quantum dots and immune cells. Small. 2011; 7:334-341.
47. Fu A, Gu W, Boussert B, Koski K, Gerion D, Manna L, Le Gros M, Larabell CA, Alivisatos AP. Semiconductor quantum rods as single molecule fuorescent biological labels. Nano Lett. 2007; 7:179-182.
48. Quarta A, Ragusa A, Deka S, Tortiglione C, Tino A, Cingolani R, Pellegrino T. Bioconjugation of rod-shaped fuorescent nanocrystals for efcient targeted cell labeling. Langmuir. 2009; 25:12614-12622.
49. Deka S, Quarta A, Lupo MG, Falqui A, Boninelli S, Giannini C, Morello G, De Giorgi M, Lanzani G, Spinella C, Cingolani R, Pellegrino T, Manna L. CdSe/CdS/ZnS double shell nanorods with high photoluminescence efciency and their exploitation as biolabeling probes. J Am Chem Soc. 2009; 131:2948-2958.
50. Xu G, Yong KT, Roy I, Mahajan SD, Ding H, Schwartz SA, Prasad PN. Bioconjugated quantum rods as targeted probes for efcient transmigration across an in vitro blood-brain barrier. Bioconjug Chem. 2008; 19:1179-1185.
51. Yong KT, Hu R, Roy I, Ding H, Vathy LA, Bergey EJ, Mizuma M, Maitra A, Prasad PN. Tumor targeting and imaging in live animals with functionalized semiconductor quantum rods. ACS Appl Mater Interfaces. 2009; 1:710-719.
52. Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 2001; 3:33-42.
53. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000; 60:2632-2635.
54. Fujimoto J, Aoki I, Khatun S, Toyoki H, Tamaya T. Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann Oncol. 2002; 13:430-434.
55. Chen Z, Malhotra PS, Tomas GR, Ondrey FG, Dufey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C. Expression of proinfammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999; 5:1369-1379.
56. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol. 1998; 152:93-100.
57. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Infuence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002; 62:3369-3372.
58. Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, Kasid UN. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol. 2009; 480:65-83.
59. Yong KT, Qian J, Roy I, Lee HH, Bergey EJ, Tramposch KM, He S, Swihart MT, Maitra A, Prasad PN. Quantum rod bioconjugates as targeted probes for confocal and two-photon fuorescence imaging of cancer cells. Nano Lett. 2007; 7:761-765.
60. Dong W, Guo L, Wang M, Xu S. CdTe QDs-based prostate-specifc antigen probe for human prostate cancer cell imaging. J Lumines. 2009;129:926-930.
61. Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, Webb WW. Water-soluble quantum dots for multiphoton fuorescence imaging in vivo. Science. 2003; 300:1434-1436.
62. Jiang W, Mardyani S, Fischer H, Chan WCW. Design and characterization of lysine cross-linked mercapto-acid biocompatible quantum dots. Chemistry of Materials. 2006;18:872-878.
63. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002 298:1759-1762.
64. Erogbogbo F, Yong KT, Roy I, Xu G, Prasad PN, Swihart MT. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano. 2008; 2:873-878.
65. Fu A, Gu W, Boussert B, Koski K, Gerion D, Manna L, et al. Semiconductor quantum rods as single molecule fuorescent biological labels. Nano Lett. 2007;7:179-182.
66. Liu W, Choi HS, Zimmer JP, Tanaka E, Frangioni JV, Bawendi M. Compact cysteine-coated CdSe(ZnCdS) quantum dots for in vivo applications. J Am Chem Soc. 2007; 129:14530-14531.
67. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004; 22:969-976.
68. Gerion D, Pinaud F, Williams SC, Parak WJ, Zanchet D, Weiss S, et al. Synthesis and properties of biocompatible water-soluble silica-coated CdSe/ZnS semiconductor quantum dots. The Journal of Physical Chemistry B. 2001;105:8861-8871.
69. Law WC, Yong KT, Roy I, Xu GX, Ding H, Bergey EJ, et al. Optically and magnetically doped organically modifed silica nanoparticles as efcient magnetically guided biomarkers for two-photon imaging of live cancer cells. The Journal of Physical Chemistry C. 2008;112:7972-7927.
70. Kumar R, Ding H, Hu R, Yong KT, Roy I, Bergey EJ, et al. In vitro and in vivo optical imaging using water-dispersible, noncytotoxic, luminescent, silica-coated quantum rods. Chemistry of Materials. 2010;22:2261-2267.
71. Duan H, Nie S. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J Am Chem Soc. 2007; 129:3333-3338.
72. Zhang LW, Yu WW, Colvin VL, Monteiro-Riviere NA. Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes. Toxicol Appl Pharmacol. 2008; 228:200-211.
73. Zhao Y, Lin K, Zhang W, Liu L. Quantum dots enhance Cu2+-induced hepatic L02 cells toxicity. J Environ Sci (China). 2010; 22:1987-1992.
74. Chen Z, Chen H, Meng H, Xing G, Gao X, Sun B, Shi X, Yuan H, Zhang C, Liu R, Zhao F, Zhao Y, Fang X. Bio-distribution and metabolic paths of silica coated CdSeS quantum dots. Toxicol Appl Pharmacol. 2008; 230:364-371.
75. Li KG, Chen JT, Bai SS, Wen X, Song SY, Yu Q, Li J, Wang YQ. Intracellular oxidative stress and cadmium ions release induce cytotoxicity of unmodifed cadmium sulfde quantum dots. Toxicol In Vitro. 2009; 23:1007-1013.
76. Rzigalinski BA, Strobl JS. Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Toxicol Appl Pharmacol. 2009; 238:280-288.
77. Hezinger AF, Tessmar J, Göpferich A. Polymer coating of quantum dots-a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm. 2008; 68:138-152.
78. Edmund AR, Kambalapally S, Wilson TA, Nicolosi RJ. Encapsulation of cadmium selenide quantum dots using a self-assembling nanoemulsion (SANE) reduces their in vitro toxicity. Toxicol In Vitro. 2011; 25:185-190.
79. Cho SJ, Maysinger D, Jain M, Röder B, Hackbarth S, Winnik FM. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir. 2007; 23:1974-1980.
80. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298:1759.
81. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem. 2004; 15:79-86.
82. Yong KT, Roy I, Ding H, Bergey EJ, Prasad PN. Biocompatible near-infrared quantum dots as ultrasensitive probes for long-term in vivo imaging applications. Small. 2009; 5:1997-2004.
83. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni J V. Renal clearance of quantum dots. Nat Biotechnol. 2007; 25:1165-1170.
84. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. Nature biotechnology. 2007;25:1165-1170.
85. Kirchner C, Liedl T, Kudera S, Pellegrino T, Muñoz Javier A, Gaub HE, Stölzle S, Fertig N, Parak WJ. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett. 2005; 5:331-338.
86. Hsieh SC, Wang FF, Lin CS, Chen YJ, Hung SC, Wang YJ. The inhibition of osteogenesis with human bone marrow mesenchymal stem cells by CdSe/ZnS quantum dot labels. Biomaterials. 2006; 27:1656-1664.
87. Su Y, He Y, Lu H, Sai L, Li Q, Li W, Wang L, Shen P, Huang Q, Fan C. The cytotoxicity of cadmium based, aqueous phase-synthesized, quantum dots and its modulation by surface coating. Biomaterials. 2009; 30:19-25.
88. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano letters. 2004;4:11-18.
89. Talapin DV, Mekis I, Goetzinger S, Kornowski A, Benson O, Weller H. CdSe/CdS/ZnS and CdSe/ZnsSe/ZnS core-shell-shell nanocrystals. Journal of Physical Chemistry B. 2004;108:18826-18831.
90. Dabbousi B, Rodriguez-Viejo J, Mikulec F, Heine J, Mattoussi H, Ober R, et al. (CdSe) ZnS core-shell quantum dots: synthesis and characterization of a size series of highly luminescent nanocrystallites. The Journal of Physical Chemistry B. 1997;101:9463-9475.
91. Erogbogbo F, Yong KT, Roy I, Hu R, Law WC, Zhao W, et al. In vivo targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals. ACS Nano. 2011;5:413-423.
92. Erogbogbo F, Tien CA, Chang CW, Yong KT, Law WC, Ding H, Roy I, Swihart MT, Prasad PN. Bioconjugation of luminescent silicon quantum dots for selective uptake by cancer cells. Bioconjug Chem. 2011; 22:1081-1088.
93. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem. 2007; 18:1391-1396.
94. Yezhelyev M V, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc. 2008; 130:9006-9012.
95. Qi L, Gao X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano. 2008; 2:1403-1410.
96. Walther C, Meyer K, Rennert R, Neundorf I. Quantum dot-carrier peptide conjugates suitable for imaging and delivery applications. Bioconjug Chem. 2008; 19:2346-2356.
97. Lee H, Kim IK, Park TG. Intracellular trafcking and unpacking of siRNA/quantum dot-PEI complexes modifed with and without cell penetrating peptide: confocal and fow cytometric FRET analysis. Bioconjug Chem. 2010; 21:289-295.
98. Jiang G, Park K, Kim J, Kim KS, Hahn SK. Target specifc intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm. 2009; 6:727-737.
99. Patil ML, Zhang M, Minko T. Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efcient intracellular siRNA delivery and gene silencing. ACS Nano. 2011; 5:1877-1887.
100. Yang M, Jin H, Chen J, Ding L, Ng KK, Lin Q, Lovell JF, Zhang Z, Zheng G. Efcient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small. 2011; 7:568-573.
101. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010; 70:3687-3696.
102. Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small. 2010; 6:1185-1190.
103. Guo S, Huang Y, Jiang Q, Sun Y, Deng L, Liang Z, Du Q, Xing J, Zhao Y, Wang PC, Dong A, Liang XJ. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano. 2010; 4:5505-5511.
104. Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2010; 6:239-246.
105. Podesta JE, Al-Jamal KT, Herrero MA, Tian B, Ali-Boucetta H, Hegde V, Bianco A, Prato M, Kostarelos K. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small. 2009; 5:1176-1185.
106. Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong KT, Roy I, Aalinkeel R, Nair B, Reynolds JL, Sykes DE, Imperiale MA, Bergey EJ, Schwartz SA, Prasad PN. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009; 1282:142-155.
107. Bonoiu AC, Mahajan SD, Ding H, Roy I, Yong KT, Kumar R, Hu R, Bergey EJ, Schwartz SA, Prasad PN. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci USA. 2009; 106:5546-5550.
108. Kopwitthaya A, Yong KT, Hu R, Roy I, Ding H, Vathy LA, Bergey EJ, Prasad PN. Biocompatible PEGylated gold nanorods as colored contrast agents for targeted in vivo cancer applications. Nanotechnology. 2010; 21:315101.
109. Ding H, Yong KT, Roy I, Pudavar HE, Law WC, Bergey EJ, et al. Gold nanorods coated with multilayer polyelectrolyte as contrast agents for multimodal imaging. The Journal of Physical Chemistry C. 2007;111:12552-12557.
110. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995; 92:7297-7301.
111. Dheur S, Dias N, van Aerschot A, Herdewijn P, Bettinger T, Rémy JS, Hélène C, Saison-Behmoaras ET. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev. 1999; 9:515-525.
112. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ter. 2005; 12:461-466.
113. Crooke ST. Antisense therapeutics. Biotechnol Genet Eng Rev. 1998; 15:121-157.
114. Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene. 2000; 19:6651-6659.
115. Guinot P, Temsamani J. [Antisense oligonucleotides: a new therapeutic approach]. Pathol Biol. 1998; 46:347-354.
116. Temsamani J, Guinot P. Antisense oligonucleotides: a new therapeutic approach. Biotechnol Appl Biochem. 1997; 26 (Pt 2):65-71.
117. Tamm I, Dörken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet. 2001; 358:489-497.
118. Webb MS, Zon G. Preclinical and clinical experience of antisense therapy for solid tumors. Curr Opin Mol Ter. 1999 1:458-463.
119. Agrawal S, Akhtar S. Advances in antisense efcacy and delivery. Trends Biotechnol. 1995; 13:197-199.
120. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med. 1996; 334:316-318.
121. Olie RA, Zangemeister-Wittke U. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential. Drug Resist Updat. 2001; 4:9-15.
122. Minko T, Patil ML, Zhang M, Khandare JJ, Saad M, Chandna P, Taratula O. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol. 2010; 624:281-294.
123. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011; 40:447-464.
124. Li Y, Duan X, Jing L, Yang C, Qiao R, Gao M. Quantum dot-antisense oligonucleotide conjugates for multifunctional gene transfection, mRNA regulation, and tracking of biological processes. Biomaterials. 2011; 32:1923-1931.
125. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006; 244:164-171.
126. Rosser CJ, Gaar M, Porvasnik S. Molecular fngerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? BMC Cancer. 2009; 9:225.
127. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ter. 2008; 15:413-448.
128. Hashimoto Y, Naruyama H, Ando R, Okada S, Tozawa K, Kohri K. [Molecular targeted therapy for prostate cancer]. Hinyokika Kiyo. 2008; 54:57-61.